I-SPY 2 TRIAL cited in President's Council of Advisors on Science and Technology report on Innovation in Drug Discovery and Development

A report from the President’s Council of Advisors on Science and Technology, released on September 25, 2012, cites an urgent need to reform the process of researching, testing and approving new drug treatments for patients. Despite many breakthroughs in biomedical research, leading to an increasing understanding of cancer, heart disease, diabetes, and other devastating diseases, the pace of new therapeutic development has not kept up with the explosion in scientific knowledge. The number of novel drugs has remained constant for several decades, even as R&D budgets have substantially increased over the past 25 years.

Among its many recommendations for improvements, the reports cites I-SPY 2 as an “exciting, innovative model for clinical trials”. The report contains a full description of the I-SPY 2 Trial.

Read the full PCAST report

Read the press release